Scientists test 'Vaccine' to train immune system to fight advanced lung cancer
NCT ID NCT05254184
Summary
This early-stage study is testing a new combination treatment for people with advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation. The treatment combines a personalized vaccine designed to target the cancer's mutation with two existing immunotherapy drugs (nivolumab and ipilimumab). The main goals are to see if this three-part combination is safe and to get an early look at whether it helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.